The €100 Billion Industry Nobody Talks About

Every conversation about Ireland's life sciences success starts with the same handful of household names and the same enormous export figure. What almost nobody talks about is the layer underneath — the vial makers, validation engineers, cold-chain hauliers and training colleges that quietly make the whole thing physically possible.

The headline number is genuinely striking. Pharmaceutical exports from Ireland reached €139 billion in 2025, according to a Goodbody economic analysis prepared for the Irish Pharmaceutical Healthcare Association, representing 53 per cent of all Irish goods exports that year. BioPharmaChem Ireland, the Ibec group representing the sector, puts direct employment at almost 50,000 people across more than 90 sites, rising to over 80,000 once indirect roles are counted. Those figures get repeated often. What they leave out is who, exactly, keeps those 90-plus sites running day to day — because it is rarely the multinational's own staff alone.

The engineers who validate everything before it starts

Before a single batch of medicine or a single medical device rolls off an Irish production line, an enormous amount of unseen work has already happened. Cleanrooms have to be qualified, sterile filling lines validated, and every piece of equipment calibrated against exacting regulatory standards before a manufacturer can even apply for approval. That work is carried out by a dense layer of Irish contract engineering, commissioning and validation firms who specialise in exactly this kind of compliance-heavy, precision-driven project work.

It is unglamorous, highly technical labour, and it has to be repeated constantly, because every new product line, every process change and every regulatory update triggers another round of qualification. It is also, in effect, the entry ticket for the entire sector: without a deep bench of local engineers who understand Good Manufacturing Practice inside out, none of the multinational investment that IDA Ireland attracts each year would be able to start production quickly once it lands.

Glass, vials and the packaging nobody notices

A finished medicine is not just an active ingredient. It is that ingredient combined with a sterile vial or syringe, a stopper, a label that meets multiple national regulatory formats, and packaging engineered to survive shipping, temperature swings and years on a pharmacy shelf. Getting that combination right, and getting it right at the enormous volumes Irish sites now produce, is its own specialised industry.

This matters more than ever given how the shape of Irish pharma exports has shifted. Exports of hormones and their derivatives — the category that includes key ingredients for GLP-1 weight-loss medicines such as semaglutide and tirzepatide — rose from €14 billion in 2024 to €51 billion in 2025, according to the Goodbody report for IPHA, drawing on Central Statistics Office trade data. Each of those billions in ingredient exports still has to be packaged, labelled and shipped correctly at the other end of the supply chain, whether that final formulation step happens in Ireland or overseas. The packaging and glass specialists who serve this trade rarely appear in press releases, but their capacity constraints or expansions can matter just as much as a new production suite.

Cold chain, calibration and the logistics that never stop

Many of the medicines now manufactured in Ireland, particularly biologics and the newer generation of injectable therapies, must be kept within tight temperature bands from the moment they leave a production line until they reach a patient. That requirement has built up a specialist Irish cold-chain logistics sector: refrigerated haulage, temperature-monitored warehousing, and freight forwarders who understand the paperwork and physical handling that pharmaceutical-grade shipping demands.

Sitting alongside that logistics layer is metrology and calibration — the practice of certifying that every thermometer, scale, sensor and piece of test equipment in a regulated facility is measuring accurately. It sounds mundane. It is, in fact, a legal requirement that recurs constantly across every site, and it is delivered by dedicated calibration and instrumentation firms that most people outside the industry will never have heard of, despite the fact that a single uncalibrated sensor can hold up an entire batch release.

The training pipeline that supplies the operators

None of this works without people trained to do it, and Ireland has built a distinctive answer to that problem. The National Institute for Bioprocessing Research and Training, based in Dublin, operates an 8,300-square-metre simulated manufacturing facility where trainees get hands-on experience with the same upstream, downstream and fill-finish equipment used in real biopharmaceutical plants, according to NIBRT's own 2025 training catalogue. Its short courses, online academy and Springboard+ programmes, delivered in partnership with Irish universities and co-funded by the Government of Ireland and the European Union, are designed specifically to move people into biopharma operator, quality control and technical roles.

That training model reaches well beyond Dublin. Technological University of the Shannon runs a Master's in Biopharmaceutical Technology from its Athlone campus that combines lectures and laboratory work with a dedicated placement at NIBRT, building on biotechnology programmes it has run since 1996. Atlantic Technological University, Technological University of the Shannon and Munster Technological University jointly deliver the Manufacturing Technician and Manufacturing Engineer apprenticeships developed by Irish Medtech, the Ibec trade association for the sector — earn-and-learn programmes that, according to Ibec, have registered more than 600 apprentices since they launched in 2017, with a 40 per cent increase in annual registrations as the sector's need for skilled operators has grown. Munster Technological University has gone further still, co-designing a tertiary-level Bachelor of Science in Process Manufacturing Practice and Technology with an education and training board in Cork specifically to feed operator and technician roles in biopharmaceutical, pharmaceutical, food and chemical manufacturing.

The scale of what these institutions are feeding into is considerable. IDA Ireland's 2025 annual results show client-company employment reaching 312,468 people, an all-time high, with the agency supporting 323 new investments during the year — the highest number it has ever recorded in a single year. Life sciences is one of the sectors most reliant on that steady flow of newly trained technicians, engineers and quality specialists, because every new investment and every production expansion needs people who already understand cleanroom discipline and regulatory documentation on day one.

Why the invisible layer matters more now

The same Goodbody report for IPHA notes that US trade policy risk toward the pharmaceutical sector persists even though tariffs were ultimately averted, a reminder that the sector operates in a shifting international environment. BioPharmaChem Ireland's director, Sinead Keogh, has pointed to "increasing global competition for investment in the sector" as the backdrop to the industry's own 2025 conference theme of "Realising the Potential of the Ecosystem." The constructive response from within the industry has been to double down on exactly the domestic strengths described above: BioPharmaChem Ireland's recent budget submissions to Government have specifically prioritised investment in skills and talent, alongside innovation infrastructure, as the pillars it wants Ireland to build on.

That framing matters because it points to where Ireland's genuine competitive advantage sits. Any country with capital can build a factory. Far fewer can supply, at short notice and at scale, the validation engineers, calibration technicians, cold-chain specialists and NIBRT-trained operators needed to run it to global regulatory standard from the day it opens. The Department of Enterprise, Tourism and Employment's Annual Employment Survey for 2025 recorded that jobs across Enterprise Ireland, IDA and Údarás na Gaeltachta client companies reached a record 554,608, with those firms purchasing more than €84 billion in goods and services from the local economy in 2024. A meaningful share of that local spending is precisely the invisible supply chain this piece has described: the engineering firms, packaging suppliers, hauliers and training providers that never appear on a factory's nameplate.

The Bottom Line

Ireland's €100 billion-plus life sciences export figure is real, verified and repeated in report after report, but it describes only the visible tip of the sector. The reason global manufacturers keep choosing Ireland, and keep expanding once they arrive, is the dense, largely unnoticed ecosystem underneath: engineers who can validate a cleanroom in weeks rather than months, packaging and cold-chain specialists who can move sensitive biologics safely across the world, and a training pipeline running through NIBRT, TUS, ATU and MTU that keeps producing operators who already speak the language of regulatory compliance. That infrastructure took decades to build, cannot be replicated overnight by a rival location, and deserves far more credit than it currently gets.